Cml therapy
CA 2303765 A1 · Owner: Schering Corporation · Inventors: Rose, Esther Helen; Rybak, Mary Ellen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for treating treatment-naive as well as treatment-experienced patients havingCML to achieve at least a partial cytogenetic response involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g. pegylated interferon alfa-2b as monotherapy or in association with a therapeutically effective amount of Ara-C are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 6, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.